Eris Lifesciences

Banks, IT lift Sensex 355 pts higher, Nifty atop 17,100; auto, pharma dip

CLOSING BELL: IT major TCS ended marginally in red amid high volatility a day after Gopinathan's resignation. In the broader markets, realty stocks also ended with solid gains.

Eris down 4% in 2 days post acquisition of 9 derma brands from Dr Reddy's

Eris Life said that the transaction would help augment and expand cosmetic dermatology business of the company through their product offerings

Stocks to watch: TCS, Patanjali Foods, Glenmark Pharma, Vi, DLF, Eris Life

Stocks to watch today: From TCS to Patanjali Foods, here are stocks to watch out in Friday's trading session

Eris Lifesciences buys dermatology brands from Dr Reddy's for Rs 275 crore

In January Eris had bought some derma brands from Glenmark Pharma as well

Eris Lifesciences Ltd buys 9 dermatology brands from Dr Reddy's for $33 mn

Eris and Dr. Reddy's did not immediately respond to Reuters' requests seeking the names of the dermatology brands

Trading Strategies in Bandhan Bank, Eris Lifesciences by Mehul Kothari

According to the technical analyst from Anand Rathi, Bandhan Bank can be shorted for a price target of Rs 272, while Eris Lifesciences can be bought for a target of Rs 800.

Boehringer Ingelheim obtains ad-interim injunctions on 4 Indian pharma cos

The firms had launched generic versions of Boehringer's patent-protected drug Linagliptin, which is marketed under the brand name Trajenta

Eris acquires Oaknet Healthcare for Rs 650 cr for dermatology foray

With a revenue base of Rs 195 crore in FY22, Oaknet brings a portfolio of leading brands in dermatology and women's health to the Eris stable.

Eris sees a sweet spot as it forays into insulin market, eyes 10% share

Eris Lifesciences (Eris) is foraying into an oligopolistic insulin market with its own insulin brand this month

Eris Lifesciences Q3 PAT up 12% to Rs 90 cr, revenue rises 7%

The company launched four new products in the first nine months of FY22, more on the anvil

Eris Lifesciences soars 10% on JV with MJ Biopharm to enter insulin segment

The purpose of entering into the agreement is expansion of product portfolio to offer biotherapeutic options to the patients in cardio-metabolic segment, Eris said in statement

Eris Lifesciences forms JV with MJ Biopharm to enter insulin segment

Eris MJ Biopharm, the 70:30 joint venture (with Eris holding a 70 per cent stake), would primarily engage in marketing and distribution of human and analogue insulin

Eris Lifesciences Q4 PAT up 21% YoY on strong show by superspecialty biz

Consolidated total income up 13%; robust anti-diabetic sales, new product pipeline, expanded coverage of cardiologists support better numbers

Eris Lifesciences Q3 net up 42% to Rs 90 cr, total income rises by 14%

Overall, the company saw decent growth in its product segments, led by cardio metabolic and vitamin-mineral-nutrients

Eris Lifesciences' Q2 net rises 16%, consolidated income grows 14.5%

Eris continued to demonstrate strong focus on its top 15 power brands

Eris Lifesciences consolidated Q4 PBT up 5.9% at Rs 62 cr, income rises 9%

Full-year pre-tax profit up 4.46% at Rs 331.52 cr

Eris Lifesciences soars 7%, hits five-month high in a weak market

In October, some large domestic mutual funds took an aggressive position in the stock, monthly disclosures show

Eris Lifesciences surges 7%, hits 5-month high in a weak market

In the past one month, the stock has outperformed the market by surging 17 per cent, as compared to a marginal 0.35 per cent rise in the S&P BSE Sensex.

Eris Lifesciences climbs 3% after it acquires trademark Zomelis for $13 mn

Used in the treatment of type 2 diabetes, Zomelis comes under a new class of anti-diabetic drugs known as DPP 4 inhibitors.

Eris Lifesciences gains 6% as 3% equity changes hands via block deals

Around 3.82 million equity shares, representing 2.78 per cent of total equity, of Eris Lifesciences changed hands on the BSE, the exchange data shows.